DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Read Disclaimer

Track explosive biotech opportunities with Biotech Fury – your real-time guide to small-cap pharmaceutical companies with breakthrough potential. Focus on FDA approvals, clinical trial catalysts, and regulatory milestones that drive stock price surges. Comparative Report: MBRX, CCCC, COYA, CUE | Report Comparativo

? Comparative Report / Report Comparativo

MBRX | CCCC | COYA | CUE – Analisi Target, Finanziari e Catalyst

? Updated / Aggiornato: November 13, 2025

? Moleculin Biotech

NASDAQ: MBRX
$0.49
Market Cap: $23.7M

? Target Price

Bull: $4.00 – $8.00 (avg $5.00)
Upside: +1,142% ?
Bear: Sub-$0.30 (trial failure risk)
Rating: Strong Buy (2 Buy, 1 Sell)

? Financial Overview

Cash Q2 2025 $7.56M
Debt $0.45M
Equity -$7.2M ⚠️
Burn Rate $5-6M/Q
Runway Mid 2026
Net Loss 2024 -$21.76M

? Key Catalysts

MIRACLE Trial – Phase 3 AML
  • Q4 2025: 45th patient enrollment + first unblinding
  • H1 2026: Second unblinding
  • Trial: Global (US, EU, Middle East) with Annamycin
  • Status: 13 patients enrolled (Sept 2025)
  • FDA: Fast Track + Orphan Drug designation
⚠️ HIGH RISK

Negative equity, high burn rate, everything depends on MIRACLE results. Strong dilution likely.

? C4 Therapeutics

NASDAQ: CCCC
$2.45
Market Cap: $228M

? Target Price

Bull: $10.00
Upside: +308% ?
Consensus: $8.50 (+247%)
Rating: Strong Buy/Hold (4 Buy, 2 Hold, 1 Sell)

? Financial Overview

Cash Q3 2025 $199.8M
Oct Raise 2025 +$125M ✅
Total Cash $324.8M ✅
Runway End 2028 ✅
Revenue Q3 $11.2M
Burn Rate ~$30M/Q

? Key Catalysts

TORPEDO Platform – Protein Degradation
  • Cemsidomide: Phase 1/2 MM & NHL – 36% ORR (ASH data)
  • Q1 2026: Phase 2 MOMENTUM combo trial
  • CFT1946: BRAF V600X solid tumors – Data H2 2025
  • $125M Raise: Oct 2025 – Funding through end 2028
  • Biogen: Partnership milestone $8M already triggered
⚡ MOD-HIGH RISK

Clinical-stage biotech with excellent runway (2028). High burn but abundant cash. Phase 1/2 trials.

? Coya Therapeutics

NASDAQ: COYA
$6.09
Market Cap: $103M

? Target Price

Bull: $18.00 (HC Wainwright)
Upside: +179% ?
Consensus: $16.20-$17.00 (+163%)
Rating: Strong Buy ⭐ (7/7 analysts all Buy!)

? Financial Overview

Cash Q3 2025 $28.1M
Debt $0 (debt-free) ✅
Equity $28.3M
Burn Rate $2.1M/Q ✅
Runway H2 2027 ✅
Net Loss Q3 -$2.1M (-48% YoY) ↓

? Key Catalysts

COYA 302 – Phase 2 ALS Trial (ALSTARS)
  • 2026: Phase 2 ALS data readout (KEY catalyst)
  • FDA: IND acceptance received for COYA 302 ✅
  • FTD Trial: Enrollment completed
  • COYA 303: Promising preclinical data
  • Partnership: $3.6M Q3 revenue from DRL collaboration
⚡ MOD-HIGH RISK

Excellent balance sheet (debt-free, runway 2027). Everything depends on ALS readout 2026. Unanimous analyst support.

? Cue Biopharma

NASDAQ: CUE
$0.70
Market Cap: $60M

? Target Price

Bull: $6.00-$8.00 (Stifel)
Upside: +757-1,043% ??
Consensus: $4.00 (+471%)
Rating: Strong Buy (4 analysts all Buy)

? Financial Overview

Cash Q3 2025 $11.7M ⚠️
Debt $2.4-6.6M
Equity $18.2M
Burn Rate $8.5M/Q ⚠️
Runway 3-4 Q ⚠️⚠️
Revenue TTM $8M (collab)

? Key Catalysts

CUE-401 & ImmunoScape Deal
  • Q4 2025: $10M payment from ImmunoScape ?
  • Nov 2026: $5M second payment
  • Equity: 40% stake in ImmunoScape
  • Milestones: Up to $345M potential
  • CUE-101: HPV+ cancer – 50% ORR, 88% OS@12mo
? VERY HIGH RISK

Going concern notice! Runway <1 year. Critical dependency on Q4 2025 ImmunoScape payment. High dilution inevitable.

? Quick Comparison Table / Tabella Comparativa

CompanyPriceMarket CapTarget UpsideCash RunwayRiskCatalyst Timeline
MBRX$0.49$24M+1,142%Mid 2026HighQ4 2025-H1 2026
CCCC$2.45$228M+246-308%End 2028Mod-High2025-2026 (Phase 2)
COYA$6.09$103M+163%H2 2027Mod-High2026 (ALS readout)
CUE$0.70$60M+471%3-4 Q ⚠️Very HighQ4 2025 (funding)

? Investment Summary / Sintesi Investitori

? BEST RISK/REWARD: COYA

  • ✅ Unanimous analyst consensus (7/7 all Buy)
  • ✅ Best balance sheet in biotech sector (debt-free, $28M cash)
  • ✅ Runway to H2 2027
  • ✅ Burn rate declining (-48% YoY)
  • ✅ Upside +163% with contained downside
  • RECOMMENDATION: BUY for 2-5 years, target ALS readout 2026

? SECOND CHOICE: CCCC (C4 Therapeutics)

  • ✅ Runway to end 2028 (excellent)
  • ✅ $125M raise just completed (Oct 2025)
  • ✅ TORPEDO protein degradation platform
  • ✅ Upside +246-308%
  • RECOMMENDATION: BUY for 1-2 years, watch Phase 2 trials 2026

? HIGH RISK SPECULATION: MBRX

  • ? Upside +1,142% if MIRACLE trial positive
  • ? Q4 2025 catalyst imminent (critical data)
  • ? High failure risk if trial negative
  • RECOMMENDATION: Max 1% of portfolio for speculators only

? SURVIVAL BET: CUE

  • ⚠️ Going concern – survival depends on Q4 2025 ImmunoScape payment
  • ⚠️ Runway <1 year (critical)
  • ⚠️ Upside +471-1,043% if saves
  • RECOMMENDATION: Avoid unless extreme risk taker. Max 0.5% if any

? Report Date: November 13, 2025

⚠️ DISCLAIMER: This report is for informational purposes only and does not constitute financial advice. Investing in biotech, especially small-cap, carries extreme risks including total capital loss. Always consult a licensed financial advisor before investing.

MerlinTrader AI Research • Data from SEC filings, Bloomberg, Yahoo Finance, Analyst Reports